Looking Ahead: The Future Of Cell Therapy In Oncology

For the field of cell therapy, the future is promising. With chimeric antigen receptor T-cell (CAR-T) therapies steadily advancing, there are now numerous FDA approved therapies for patients with blood-borne cancers, including B-cell non-Hodgkin’s lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). In fact, the FDA recently approved Abecma (idecabtagene vicleucel), the first cell therapy approved by the FDA for heavily pre-treated adult patients with multiple myeloma.

However, in the face of these advancements, there are still challenges to overcome, including the length of time required to manufacture cell therapies, high costs, and logistical challenges.